N-Desmethyladinazolam (BioDeep_00000181278)

   

human metabolite blood metabolite


代谢物信息卡片


({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)(methyl)amine

化学式: C18H16ClN5 (337.1094)
中文名称:
谱图信息: 最多检出来源 Homo sapiens(blood) 96.67%

分子结构信息

SMILES: CNCC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
InChI: InChI=1S/C18H16ClN5/c1-20-10-16-22-23-17-11-21-18(12-5-3-2-4-6-12)14-9-13(19)7-8-15(14)24(16)17/h2-9,20H,10-11H2,1H3

描述信息

同义名列表

7 个代谢物同义名

({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)(methyl)amine; mono-N-Demethyladinazolam mesylate; N-Desmethyladinazolam mesylate; mono-N-Desmethyladin azolam; mono-N-Demethyladinazolam; N-Desmethyladinozolam; N-Desmethyladinazolam



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Karthik Venkatakrishnan, Kerry E Culm, Bruce L Ehrenberg, Jerold S Harmatz, Kathleen E Corbett, Joseph C Fleishaker, David J Greenblatt. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. Journal of clinical pharmacology. 2005 May; 45(5):529-37. doi: 10.1177/0091270004269105. [PMID: 15831776]
  • A D Fraser, W Bryan. Evaluation of the Abbott TDx serum benzodiazepine immunoassay for the analysis of lorazepam, adinazolam, and N-desmethyladinazolam. Journal of analytical toxicology. 1995 Sep; 19(5):281-4. doi: 10.1093/jat/19.5.281. [PMID: 7500613]
  • P L Golden, P E Warner, J C Fleishaker, R C Jewell, S Millikin, J Lyon, K L Brouwer. Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans. Clinical pharmacology and therapeutics. 1994 Aug; 56(2):133-41. doi: 10.1038/clpt.1994.116. [PMID: 8062489]
  • J H Chambers, J C Fleishaker. The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam. Biopharmaceutics & drug disposition. 1994 May; 15(4):263-72. doi: 10.1002/bdd.2510150402. [PMID: 8068865]
  • J C Fleishaker, J H Greist, J W Jefferson, A Q Sheridan. Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder. Journal of clinical psychopharmacology. 1994 Feb; 14(1):28-35. doi: NULL. [PMID: 8151001]
  • A D Fraser, A F Isner, W Bryan. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC. Journal of analytical toxicology. 1993 Nov; 17(7):427-31. doi: 10.1093/jat/17.7.427. [PMID: 8309217]
  • J C Fleishaker, T A Sisson, J J Sramek, J Conrad, A E Veroff, N R Cutler. Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test battery. Journal of clinical pharmacology. 1993 May; 33(5):463-9. doi: 10.1002/j.1552-4604.1993.tb04689.x. [PMID: 8331205]
  • J C Fleishaker, L K Hulst, S A Ekernäs, A Grahnén. Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. Journal of clinical psychopharmacology. 1992 Dec; 12(6):403-14. doi: NULL. [PMID: 1474178]
  • A B Suttle, S S Songer, G E Dukes, L J Hak, M Koruda, J C Fleishaker, K L Brouwer. Ranitidine does not alter adinazolam pharmacokinetics or pharmacodynamics. Journal of clinical psychopharmacology. 1992 Aug; 12(4):282-7. doi: NULL. [PMID: 1527233]
  • J C Fleishaker, C E Wright. Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administration. Pharmaceutical research. 1992 Apr; 9(4):457-63. doi: 10.1023/a:1015875910222. [PMID: 1495889]
  • J C Fleishaker, L K Hulst, T C Smith, H Friedman. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in health volunteers. European journal of clinical pharmacology. 1992; 42(3):287-94. doi: 10.1007/bf00266350. [PMID: 1577047]
  • P D Kroboth, R A Maxwell, J C Fleishaker, D H Van Thiel, R B Smith. Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects. Journal of clinical pharmacology. 1991 Jun; 31(6):580-6. doi: 10.1002/j.1552-4604.1991.tb03741.x. [PMID: 1880225]
  • J C Fleishaker, T C Smith, H Friedman, J P Phillips. N-desmethyladinazolam pharmacokinetics and behavioral effects following administration of 10-50 mg oral doses in healthy volunteers. Psychopharmacology. 1991; 105(2):181-5. doi: 10.1007/bf02244306. [PMID: 1796125]
  • J C Fleishaker, H Friedman, S R Pollock, T C Smith. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate after single oral doses of each compound in healthy volunteers. Clinical pharmacology and therapeutics. 1990 Dec; 48(6):652-64. doi: 10.1038/clpt.1990.209. [PMID: 2249377]
  • J C Fleishaker, J P Phillips. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers. Psychopharmacology. 1989; 99(1):34-9. doi: 10.1007/bf00634449. [PMID: 2506603]